Trial Profile
Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs INO 5150 (Primary) ; INO 9012
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 22 Oct 2018 Results presented in an Inovio Pharmaceuticals media release.
- 22 Oct 2018 According to an Inovio Pharmaceuticals media release, results from this study were presented at the European Society for Medical Oncology (ESMO) 2018 congress.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology